Johnson & Johnson
JNJJohnson & Johnson is a global healthcare platform that converts scientific innovation and brand trust into durable, high-margin cash flows.
Because few companies combine 70% gross margins, steady growth, and century-long staying power in one package.
Business Model
Patented drugs and medical devices
It sells prescription medicines and surgical tools that hospitals, insurers, and patients rely on every day.
Economic Engine
High-margin innovation
Patents and specialized products support a 72.8% gross margin and 27.2% operating margin.
Long-Term Lens
Pipeline durability
The key question is whether new drugs and devices can replace aging products as patents expire.
BinaPrint Snapshot
Style
Harvest
Fitness
Strong
Updated Mar 8, 2026
On this page
Company Story
How do Johnson & Johnson's business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A diversified healthcare powerhouse with strong margins and global scale, built to compound steadily, but dependent on constant drug innovation to stay ahead.”
What does Johnson & Johnson actually do?
Johnson & Johnson develops and sells prescription medicines and medical devices used in hospitals and clinics around the world.
- Discovers and markets drugs for cancer, immune disorders, and other serious diseases
- Makes surgical equipment and orthopedic implants used in operations
- Operates at global scale with 138,100 employees
Why it matters
Healthcare demand is persistent
People need treatment in good and bad economies, which makes healthcare spending more resilient than many industries.
How does Johnson & Johnson make money?
It earns money by selling high-value medicines protected by patents and specialized medical devices to hospitals and healthcare systems.
- Gross margin of 72.8%, meaning most revenue remains after production costs
- Operating margin of 27.2%, showing strong pricing power
- Free cash flow margin of 20.9%, turning sales into real cash
Economic clue
Pricing power from innovation
High margins suggest customers pay for differentiated products rather than commodities.
Why do long-term investors keep Johnson & Johnson on the radar?
It combines steady growth with strong profitability in an industry supported by aging populations and rising global healthcare spending.
- Revenue grew 6.0% year over year and 4.6% on average over five years
- Earnings per share grew 8.6% on average over five years
- Margins are expanding, improving the quality of growth
Investor takeaway
Steady compounding profile
Mid-single-digit revenue growth paired with expanding margins can translate into long-term earnings growth.
Based on company financial statements.
What Could Change The Story
- Matured would move the profile toward Summit.
- Faded would move the profile toward Yield.
Benchmark Comparison
How has Johnson & Johnson performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,540
+54.0% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| JNJ | +54.0% | $1,540 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Johnson & Johnson
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to global healthcare growth without betting on a single drug
- High and expanding profit margins
- A business model built around recurring medical need
Be Careful If You Expect
- Rapid double-digit revenue growth year after year
- Zero regulatory or legal risk
- A business immune to patent expirations
What To Watch Over Time
- Strength of the drug development pipeline
- Impact of patent expirations on major products
- Sustained operating margin above 25%
BinaPrint Position
Where does Johnson & Johnson sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for Johnson & Johnson right now?
Three durable business metrics that matter more than day-to-day price moves.
4.6% average over 5 years
8.6% average over 5 years
72.8% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 4.6% average over 5 years | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 8.6% average over 5 years | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 72.8% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Johnson & Johnson's fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
18.5% ROIC
72.8% gross margin
20.9% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 18.5% ROIC | The business is currently showing good capital efficiency. |
| Profitability | 72.8% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 20.9% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Johnson & Johnson?
Johnson & Johnson currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Johnson & Johnson?
Company-specific questions readers often ask about Johnson & Johnson.
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Johnson & Johnson develops prescription medicines and medical devices that hospitals, doctors, and patients use to treat serious diseases and perform surgeries.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Healthcare demand rises with aging populations, and chronic diseases like cancer and autoimmune disorders are increasing globally, supporting steady long-term demand for its medici...
A 72.8% gross margin and 27.2% operating margin provide financial firepower to fund research, withstand pricing pressure, and outspend smaller rivals.
Diversification across drugs and medical devices reduces reliance on any single product and smooths revenue over time.
Global scale and regulatory expertise make it difficult for smaller competitors to replicate its pipeline and distribution reach.
Bear case
What can break
Patent expirations can abruptly erode revenue as generic competitors enter, potentially cutting sales of major drugs by 50% or more within a few years.
Drug pricing reform in the United States or other large markets could compress margins and reduce returns on research spending.
Scientific failure in the development pipeline could leave revenue growth stalled for years if new blockbusters do not replace aging products.
Large legal liabilities tied to product safety or historical claims could drain cash and damage brand trust.
Risk Radar
Key Risks
Where downside pressure can build.
Patent concentration risk, if a handful of blockbuster drugs represent a large share of profit and lose exclusivity, revenue from those products could fall sharply within 2 to 3 years.
Regulatory risk, with significant exposure to United States healthcare policy changes that could pressure a 28.5% net margin.
Research risk, as billions in annual research spending may not yield commercially successful drugs.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $240.40
- Daily move
- +0.32%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.